Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.58 |
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29853379 | 0.89 | MEN1 (0.58) | ADORA2AADORA1HDAC6HDAC1HDAC4 | |
| SCHEMBL946430 | 0.89 | MEN1 (0.58) | ADORA2AADORA1HDAC6HDAC1HDAC4 | |
| SCHEMBL25547980 | 0.84 | HDAC6 (0.69) | ADORA2AHDAC6HDAC1HDAC4HSP90AA1 | |
| SCHEMBL21977307 | 0.84 | HDAC6 (0.69) | ADORA2AHDAC6HDAC1HDAC4HSP90AA1 | |
| SCHEMBL25511872 | 0.84 | MEN1 (0.59) | ADORA2AADORA1MEN1LMNAKMT2A | |
| SCHEMBL29761011 | 0.83 | HSP90AA1 (0.59) | ADORA2AADORA1HDAC6HDAC1HDAC4 | |
| SCHEMBL23388585 | 0.83 | HSP90AA1 (0.59) | ADORA2AADORA1HDAC6HDAC1HDAC4 | |
| SCHEMBL23388257 | 0.83 | HDAC6 (0.63) | ADORA2AADORA1HDAC6HDAC1HDAC4 | |
| SCHEMBL29761023 | 0.83 | HDAC6 (0.63) | ADORA2AADORA1HDAC6HDAC1HDAC4 | |
| SCHEMBL29761021 | 0.83 | HDAC6 (0.63) | ADORA2AADORA1HDAC6HDAC1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606564-B2 | Adenosine receptor antagonist compounds | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2026-04-21 | — | — | US | disclosed |
| CN-116425756-B | Adenosine receptor antagonist compounds and uses thereof | 日东制药株式会社 | 2025-05-13 | — | — | CN | disclosed |
| CN-114829363-B | Adenosine receptor antagonist compounds | 日东制药株式会社 | 2024-10-01 | — | — | CN | disclosed |
| CN-116425756-A | Adenosine receptor antagonist compounds and uses thereof | 日东制药株式会社 | 2023-07-14 | — | — | CN | disclosed |
| US-20230159534-A1 | ADENOSINE RECEPTOR ANTAGONIST COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-05-25 | — | — | US | disclosed |
| US-20230159534-A1 | ADENOSINE RECEPTOR ANTAGONIST COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-05-25 | — | — | US | disclosed |
| EP-4061817-A1 | ADENOSINE RECEPTOR ANTAGONIST COMPOUNDS | Ildong Pharmaceutical Co., Ltd. (KR) | 2022-09-28 | — | — | EP | disclosed |
| CN-114829363-A | Adenosine receptor antagonist compounds | 日东制药株式会社 | 2022-07-29 | — | — | CN | disclosed |
| WO-2021099838-A1 | ADENOSINE RECEPTOR ANTAGONIST COMPOUNDS | ILDGNG PHARMACEUTICAL CO., LTD. (KR) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021099838-A1 | ADENOSINE RECEPTOR ANTAGONIST COMPOUNDS | ILDGNG PHARMACEUTICAL CO., LTD. (KR) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021099832-A2 | ADENOSINE RECEPTOR ANTAGONIST COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021099832-A2 | ADENOSINE RECEPTOR ANTAGONIST COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2021-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159534-A1 | ADENOSINE RECEPTOR ANTAGONIST COMPOUNDS | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885HDAC6 2027/4885 |
| US-12606564-B2 | Adenosine receptor antagonist compounds | ADORA2A, ADORA1, ADORA2B | ADORA2A 1/4885ADORA1 2/4885HDAC6 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.